FDA approvals

FDA approves Lotemax gel for postop inflammation and pain

The U.S. Food and Drug Administration has approved Lotemax gel drop formulation for the treatment of inflammation and pain after ocular surgery, according to a news release.

Lotemax (loteprednol etabonate ophthalmic gel 0.5%, Bausch + Lomb) is a topical corticosteroid formulation in the company’s line of loteprednol ophthalmic products.

One or two drops of Lotemax gel are applied into the conjunctival sac of the affected eye four times each day for 2 weeks after surgery. As with other corticosteroids, it is contraindicated in most viral diseases of the conjunctiva and cornea, the release said.

Adverse reactions related to Lotemax gel include anterior chamber inflammation in 5% of cases, foreign body sensation in 2% of cases and eye pain in 2% of cases, according to the release.

The U.S. Food and Drug Administration has approved Lotemax gel drop formulation for the treatment of inflammation and pain after ocular surgery, according to a news release.

Lotemax (loteprednol etabonate ophthalmic gel 0.5%, Bausch + Lomb) is a topical corticosteroid formulation in the company’s line of loteprednol ophthalmic products.

One or two drops of Lotemax gel are applied into the conjunctival sac of the affected eye four times each day for 2 weeks after surgery. As with other corticosteroids, it is contraindicated in most viral diseases of the conjunctiva and cornea, the release said.

Adverse reactions related to Lotemax gel include anterior chamber inflammation in 5% of cases, foreign body sensation in 2% of cases and eye pain in 2% of cases, according to the release.